Business
Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals
New MGTA-117 ADC clinical candidate for conditioning demonstrates broad therapeutic index; advancing MGTA-117 to generate initial patient clinical data in
About this update from Dianthus Therapeutics, Inc.
[{"type":"text","content":"\n\nNew MGTA-117 ADC clinical candidate for conditioning demonstrates broad therapeutic index; advancing MGTA-117 to generate initial patient clinical data in 2021\n\n\nMGTA-145 first-line stem cell mobilization agent on track to complete Phase 1 study and move into multiple Phase 2 studies in 2020\n\n\nCompletion of enrollment in Phase 2 study of MGTA-456 cell therapy in IMDs expected in 2020\n\n\nEight abstracts from across the pipeline accepted for presentation at Transplant and Cellular Therapy Annual Meeting, including four oral presentations, and Best Oral Abstract award\n\n\nEnded 2019 with approximately $146 million in cash and cash equivalents with runway into 4Q21\n\n\n\n \n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nMagenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today highlighted recent progress across several programs and outlined goals for 2020. These updates will be discussed during a webcast presentation at the 38th annual J.P. Morgan Healthcare Conference on Wednesday, January 15th at 11:30 a.m. PT (2:30 p.m. ET).\n\n\n“In 2019 we generated landmark data from our ADC-based targeted patient preparation platform, which is delivering a new class of antibody-drug conjugates (ADCs) that have the power to bring one-time treatment to more patients with autoimmune diseases, blood cancers and genetic diseases. We also presented clinical data for our first-line stem cell mobilization program, MGTA-145, which we are developing as the new standard of care for stem cell mobilization with the potential to benefit all of the transplant-eligible patients each year,” said Jason Gardner, D. Phil., President and Chief Executive Officer, Magenta. “As we begin 2020, we are particularly excited to unveil our MGTA-117 clinical candidate for targeted patient preparation for stem cell transplant or gene therapy. New results announced today highlight the potency, safety and broad therapeutic index of MGTA-117, well above that of currently approved ADCs. We believe that MGTA-117 is the optimal agent for depleting stem cells to enable safe immune reset. We look forward to moving this program into the clinic with initial clinical data expected in 2021.”\n\n\nTargeted Patient Preparation Programs\n\n\nCurrent methods to condition ...